Rationale and design of the PROMETCO study: A real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective

Miriam Koopman*, Carmine Pinto, György Bodoky, Rocio Garcia-Carbonero, Francisca Marti Marti, Jean Baptiste Bachet

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)

Abstract

The PROMETCO study is collecting real-world data on metastatic colorectal cancer (mCRC) patients with two progressions. This international, prospective, longitudinal, observational cohort study is collecting data on mCRC patients with two disease progressions since diagnosis and receiving subsequent treatment. Objectives include overall survival, treatment patterns, effectiveness and safety and patient-reported outcomes using the EuroQol 5-level, 5-dimensional questionnaire, the Brief Fatigue Inventory and a modified version of the ACCEPTance by the Patients of their Treatment (ACCEPT ©) questionnaire. Data are collected retrospectively and prospectively up to 18 months. As of 13 October 2021, 544 patients from 18 countries had been enrolled. To the authors' knowledge, PROMETCO is the first international, real-world study of the continuum of care of mCRC patients in this setting. Trial registration number: NCT03935763 (ClinicalTrials.gov).

Original languageEnglish
Pages (from-to)1313-1320
Number of pages8
JournalFuture Oncology
Volume18
Issue number11
DOIs
Publication statusPublished - Apr 2022

Keywords

  • Continuum of care
  • Metastatic colorectal cancer
  • Patient-reported outcomes
  • Real-world evidence
  • Study design
  • Survival
  • Treatment patterns
  • Prospective Studies
  • Humans
  • Continuity of Patient Care
  • Colorectal Neoplasms/drug therapy
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Observational Studies as Topic
  • Retrospective Studies
  • Cohort Studies

Fingerprint

Dive into the research topics of 'Rationale and design of the PROMETCO study: A real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective'. Together they form a unique fingerprint.

Cite this